Johnson & Johnson is planning a phase 3 programme for Rybrevant in colorectal cancer as a follow-up to its first indication in non-small cell lung cancer (NSCLC), after reporting encouraging results at ESMO.The new data from the phase 1b/2 OrigAMI-1 study showed that Rybrevant (amivantamab) plus chemotherapy achieved an objective response rate (ORR) of 49% in patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC) – who had not previously received anti-EGFR therapy – when used as either first- or second-line therapy.The median duration of response was 7.4 months with the regimen, while median progression-free survival (PFS) was 7.5 months, and the disease control rate – including stabilised cancers – was 88%.

强生公司（Johnson＆Johnson）在ESMO报告了令人鼓舞的结果后，正在计划为Rybrevant治疗结直肠癌的第三阶段计划，作为其在非小细胞肺癌（NSCLC）中首次适应症的后续行动。1b/2期折纸-1研究的新数据显示，Rybrevant（amivantamab）加化疗在RAS/BRAF野生型转移性结直肠癌（mCRC）患者中达到了49%的客观缓解率（ORR）-以前没有接受过抗EGFR治疗-当用作一线或二线治疗时。该方案的中位缓解时间为7.4个月，中位无进展生存期（PFS）为7.5个月，疾病控制率（包括稳定的癌症）为88%。

Rybrevant also achieved an ORR of 53% in patients whose disease had spread to the liver, which occurs commonly with this type of cancer.Moreover, 21% of patients treated with the regimen became eligible for potentially curative surgery for the cancer, according to Filippo Pietrantonio of Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy, who presented the results at ESMO and said the data shows 'the promise of Rybrevant in patients in this setting.'The go-to treatment for this type of mCRC at the moment is Eli Lilly's anti-EGFR-antibody Erbitux (cetuximab) plus chemotherapy, and J&J is planning to run a pair of phase 3 trials of Rybrevant in the first- and second-line settings to see how its drug compares.'Confirmation that Rybrevant has activity beyond lung cancer, given its unique multi-targeted approach in inhibiting EGFR and MET, is a potentially important step forward for patients with EGFR inhibitor-naïve metastatic colorectal cancer,' commented Kiran Patel, head of clinical development, solid tumours, at J&J.'Colorectal cancer is th.

Rybrevant在疾病扩散到肝脏的患者中也达到了53%的ORR，这种癌症通常发生在这种类型的癌症中。此外，意大利米兰Fondazione IRCCS Istituto Nazionale dei Tumori的Filippo Pietrantonio表示，接受该方案治疗的患者中有21%有资格接受可能治愈癌症的手术，他在ESMO上介绍了结果，并表示数据显示“Rybrevant在这种情况下对患者的承诺”目前，这种类型的mCRC的治疗方法是礼来公司的抗EGFR抗体埃尔比妥（西妥昔单抗）加化疗，强生公司计划在一线和二线环境中进行一对Rybrevant的3期临床试验，以了解其药物的比较情况鉴于其独特的多靶点抑制EGFR和MET的方法，确认Rybrevant具有肺癌以外的活性，对于EGFR抑制剂初治转移性结直肠癌患者来说是潜在的重要一步，”J＆J.'Collectal cancer is th.实体瘤临床开发负责人Kiran Patel评论道。